A safe and accurate method of early diagnosis of herpes simplex encephalitis has been an elusive goal. Herpes simplex encephalitis characteristically causes a severe encephalopathy with focal neurological symptoms and signs, but the clinical manifestations can be mimicked by other diseases.' Abnormalities on EEG,2 CT3 and MRI4 are common but they are not specific for herpes simplex encephalitis. A rise in the titre of antibodies to herpes simplex virus (HSV) in the CSF may confirm the diagnosis of herpes simplex encephalitis but HSV antigens and antibodies are rarely detectable in the early stages.57
The most accurate method of diagnosing herpes simplex encephalitis has been the isolation of HSV or viral antigens from brain tissue,8 but a brain biopsy has a risk of complications,9 it may miss a diagnosis of herpes simplex encephalitis'0 and it can provide misleading information." Furthermore, transportation of a seriously ill patient with encephalitis to a hospital that has a neurosurgical unit is risky. Many clinicians prefer to treat patients with acyclovir without confirming the diagnosis of herpes simplex encephalitis but this approach runs the risk of overlooking other diseases. ' HSV can be isolated from CSF cultures in only 4% of patients with herpes simplex encephalitis. 5 The low rate of detection of HSV may be a result of the small quantity of virus in the CSF or neutralisation of infectious virus by antibody. Virus particles that are complexed with antibody retain their nucleic acid component. The polymerase chain reaction (PCR) can amplify small quantities of selected deoxyribonucleic acid (DNA) sequences until they are detectable by conventional DNA hybridisation.'2 Evidence from small groups of patients and studies using stored CSF samples from patients with proven herpes simplex encephalitis suggests that identification of HSV DNA in CSF using the PCR may be a useful method of diagnosing herpes simplex encephalitis."1 '20 13 PCR reactions were sequentially subjected to denaturation for 3 minutes, annealing at 60°C for 30 seconds, chain elongation at 65°C for 2 minutes and denaturation at 95°C for 1 minute. Forty cycles of amplification were performed. Positive control DNA was prepared from HSV-infected human embryo fibroblasts. To monitor for potential contamination, aliquots of lysis buffer with no added DNA were processed and amplified in parallel with each batch of patient samples. Serial dilutions of purified genomic DNA showed this assay was able to detect 102 viral genome equivalents. HSV I and II amplified with equal efficiency."3 The identity of the 142 base-pair HSV I and II specific PCR product was confirmed by Southern blotting and hybridisation with a 32P-labelled oligonucleotide probe derived from an internal region of the amplimer with complete sequence homology between the two HSV types: AGC-GCC-GTC-AGC-GAG-GAT-AAC-CTG-GG. Individual virus strains were typed by restriction endonuclease digestion of the amplified product. Each of the 20 base-pair primers targeted a region of virus genome that was completely conserved between HSV types I and II. Virus genome encompassed by the two primers also was highly conserved with less than 6 base-pair variation between types I and II. Despite this close homology unique restriction sites were identified so that amplified product could be typed by digestion with HpaII and Hinfl (fig 1) .
Separate facilities and laboratory equipment were used for PCR reagent handling, DNA extraction and gel electrophoresis. Laboratory personnel with active herpes labialis were not involved in sample processing or the PCR. HSV DNA was detected in the CSF of 3 patients who had an acute meningitis and herpetic genital infection, although the virus was not isolated from CSF cultures. CSF specimens from the control patients with other neurological diseases did not contain HSV DNA.
Results

Discussion
The PCR is a highly specific and sensitive method of detecting DNA.'2 The DNA primers used in our assay are specific to HSV and will not detect DNA from other herpes viruses."3 Specific DNA sequences can be amplified by a factor of 106 within a few hours, but the exquisite sensitivity of the PCR also is its main potential drawback. 23 Contamination with amplified DNA product in the laboratory is a well recognised problem and standard procedures now include segregation of sample preparation and amplification, use of positive displacement pipettes and inclusion of multiple assay blanks with each run.
Many individuals harbour HSV and intermittently excrete the virus.2' Samples of CSF may be contaminated by medical, nursing or laboratory staff. The risk of external contamination is increased when specimens are obtained at another hospital, because they will be handled by two sets of laboratory staff. A total of 62% of our samples were sent from other hospitals and we expected that if external contamination was a problem, it would show up in this study. In the presence of a viraemia, CSF may also be contaminated by blood leucocytes during a traumatic lumbar puncture. Latent HSV infection of the brain in individuals who do not have herpes simplex encephalitis is another potential source of false-positive results. '6 Other laboratory tests supported the diagnosis of herpes simplex encephalitis in 14/20 patients with HSV DNA in the CSF. A diagnosis of herpes simplex encephalitis was not confirmed in the other 6 patients, although the clinical picture, CSF and CT suggested this was the correct diagnosis. In 3 of these patients a second CSF specimen was not examined and a brain biopsy was not obtained. In the other 3 patients, antibodies to HSV did not appear in the CSF. CSF antibodies to HSV may not appear in biopsyproven herpes simplex encephalitis8 and in patient 18 antibody production may have been blunted by chemotherapy. The diagnosis of herpes simplex encephalitis was most doubtful in patient 19, since HSV DNA was detected only in the second of 3 CSF specimens and HSV was not isolated from the brain biopsy. Nevertheless, a brain biopsy misses the diagnosis in 4% of patients with untreated herpes simplex encephalitis'l and a false-negative biopsy may be more common if acyclovir has been started.
As far as we know there were no false-negative PCR assays in the patients with a clinical diagnosis of possible herpes simplex encephalitis, but the sensitivity of the assay cannot be assessed accurately in our patients. None of the PCR-negative patients had a brain biopsy, which is the "gold standard" for the diagnosis of herpes simplex encephalitis. Since the introduction of acyclovir, many clinicians prefer to treat suspected herpes simplex encephalitis without confirming the diagnosis with a brain biopsy. Retrospective confirmation of the diagnosis by measurement of CSF antibodies is often not sought if the patient is recovering. CSF antibodies have been used as the "gold standard" for the diagnosis of herpes simplex encephalitis in most of the patients in other studies using the PCR assay for the detection of HSV DNA in CSF."520 The sensitivity of the PCR assay compares favourably with CSF antibody measurement. Until the PCR assay is compared with brain biopsy in a large number of unselected patients with suspected herpes simplex encephalitis, its true sensitivity will be uncertain.
HSV DNA occasionally has not been found in the CSF after early treatment with acyclovir. '7 We found that HSV DNA usually was present in the CSF for one to two weeks after treatment was started, and it sometimes persisted for longer. In one patient a weak signal was still present after 35 days. Other investigators found that HSV DNA persisted in the CSF for up to 27 days,'6 17 20 but it usually disappeared within 14 days. '7 18 Another possible cause of a false-negative result is failure of the primers to recognise both HSV I and II. Neonatal herpes simplex encephalitis can be caused by HSV I or II.25 HSV I is the cause in the overwhelming majority of children and adults with herpes simplex encephalitis25 but, as in patient 1, HSV II occasionally is the causative agent in adults. If the primers used in the PCR assay recognise only HSV I DNA, HSV II will not be detected. This potential source of falsenegative results was not a problem in our patients because the primers identified both types of HSV.
A third potential reason for a false-negative assay is "genomic drift" of the virus. Although HSV is genetically relatively stable, base substitution does occur.26 Some strains of HSV may be sufficiently diverse to escape primer detection.
The detection of HSV DNA in CSF by the PCR can be used as a guide to early treatment. In 19/20 patients HSV DNA was found in the first CSF specimen. Others found that HSV DNA occasionally was not present in the first CSF sample but a second specimen collected 24 hours later was positive.'7 18 The PCR assay itself is rapid and can provide a result within 24 to 48 hours.
Most clinicians continued acyclovir until HSV DNA had disappeared but it is not yet known if persistence of HSV DNA in the CSF is a useful guide to the duration of treatment. In 5 patients HSV DNA persisted beyond 10 days. All of these patients received a prolonged course of treatment and 3 had a satisfactory recovery. Other investigators have found that a relapse of herpes simplex encephalitis sometimes was heralded by the reappearance of HSV DNA in the CSF. 1820 The cost of materials for a single PCR reaction is approximately $NZ15 (C5). A high level of technical skill is required for reliable performance of the assay and supervision by an experienced molecular biologist is recommended. The test may therefore be available only in large hospitals. If the PCR assay for HSV DNA is not available locally, CSF can be sent to a laboratory that performs the test. Our experience suggests that contamination is not a significant problem when CSF is transported from other hospitals.
Our results indicate that the detection of HSV DNA in the CSF with a PCR assay is a highly specific test for herpes simplex encephalitis. The assay should detect small quantities of HSV DNA but a precise estimate of its sensitivity cannot be provided, because most patients in this and other studies did not have a brain biopsy. We believe that the PCR assay has a useful role in the early diagnosis and treatment of herpes simplex encephalitis, while a brain biopsy usually can be avoided. Acyclovir should be started immediately if the history, examination, CSF, EEG, CT scan or MRI scan suggest that herpes simplex encephalitis is a possible diagnosis. If HSV DNA is present in the CSF, a full course of acyclovir is required. A negative result should be interpreted with caution but it suggests that herpes simplex encephalitis is not the correct diagnosis and an alternative diagnosis should be sought. Unless the clinical, EEG and neuroimaging findings strongly support herpes simplex encephalitis, it is reasonable to stop acyclovir if the PCR assay is negative.
